Trade Alnylam Pharmaceuticals, Inc. - ALNY shares price

1m
5m
15m
30m
1H
4H
1D
1W
Open on web platform

Market info

Min traded quantity:
1
Full name:
Alnylam Pharmaceuticals, Inc.
Currency:
USD
Margin:
5%
Stock exchange:
United States of America
Long position overnight fee
-0.0203%
Short position overnight fee
-0.0102%

Trading hours (UTC)

Mon - Fri:
13:30 - 20:00

ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
White Paper Declaration

You might be interested in

A world first

Our advanced web platform is the world’s first regulated tokenised assets exchange.

Crypto as collateral

Trade the global financial markets using Bitcoin or Ethereum.

Security as priority

Authorised by the High Technology Park of Belarus, the European blockchain regulator, the safety of your holdings is guaranteed.

Technical indicators

Keep an eye on your positions with over 75 advanced charts, price analysis and price alerts.

Control your capital

Use stop-loss and take-profit orders to keep what you earn.

Use the world’s first regulated tokenised assets exchange to build a diverse investment portfolio with your crypto holdings. Make your deposits in Bitcoin or Ethereum to trade global financial instruments with competitive leverage and tight spreads. Currency.com keeps your holdings secure and accessible at a glance.

VISA MASTERCARD Yandex Money WIRE Faster payments SEPA PCI BTC ETH